以雄激素受体为靶标的抗前列腺癌药物筛选模型的建立和应用  

Establishment and application of a drug screening model for anti-prostate cancer agents targeting androgen receptor

作　　者：何阳[1] 刘阳光[1] 丁寄葳[1] 李晓宇[1] 岑山[1] 周金明[1] 

机构地区：[1]中国医学科学院北京协和医学院医药生物技术研究所,北京100050

出　　处：《药学学报》2016年第2期287-293,共7页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金资助项目(81001402;81311120299)

摘　　要：雄激素受体(AR)在维持前列腺的功能和促进前列腺癌形成的过程中发挥着非常重要的作用,也是前列腺癌药物治疗中的重要靶标。本研究通过构建AR活性依赖的双荧光素酶基因报告系统,在细胞水平上建立了以AR为靶点的抗前列腺癌药物筛选模型。并将该模型应用于传统中药红景天根、野生猕猴桃根、雷公藤根提取物的抗前列腺癌活性研究,为前列腺癌的治疗提供新的策略。Androgen receptor（AR） plays an important role in the maintenance of prostate function and development of prostate cancer. AR is the key target in the therapy of prostate cancer. In this study, a cell-based screening assay was established by dual-luciferase reporter system to analyze the activity of AR. In the screening assay, we detected the anti-prostate cancer activities of rhodiola root extract, wild kiwifruit root extract and tripterygium wilfordii root extract, which may provide a new strategy for the treatment of prostate cancer.

关 键 词：雄激素受体 抗前列腺癌 报告系统 传统中药 雷公藤根提取物 药物筛选 

分 类 号：R965.1[医药卫生—药理学]